PARP抑制剂在前列腺癌和尿路上皮癌中的应用
PARP Inhibitors in Prostate and Urothelial Cancers.
作者信息
Garje Rohan, Vaddepally Raju Kumar, Zakharia Yousef
机构信息
Division of Hematology, Oncology, and Blood and Marrow Transplant, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, United States.
Yuma Regional Medical Center, Yuma, AZ, United States.
出版信息
Front Oncol. 2020 Feb 7;10:114. doi: 10.3389/fonc.2020.00114. eCollection 2020.
Abstract
Poly(ADP-ribose) polymerase (PARP) inhibitors targeting DNA repair gene mutations have shown significant clinical benefit in patients with ovarian and breast cancers. In metastatic prostate cancers, the prevalence of DNA repair gene mutations is up to 20%, and early phase studies have shown clinical activity of PARP inhibitors. Numerous clinical trials with either PARP monotherapy or in combination with other therapeutic agents are ongoing in prostate cancer. In this comprehensive review, we provide the rationale, efficacy, and safety data of PARP inhibitors in prostate as well as urothelial cancers.
摘要
靶向DNA修复基因突变的聚（ADP - 核糖）聚合酶（PARP）抑制剂已在卵巢癌和乳腺癌患者中显示出显著的临床益处。在转移性前列腺癌中，DNA修复基因突变的发生率高达20%，早期研究已显示PARP抑制剂具有临床活性。目前在前列腺癌领域正在进行多项关于PARP单药治疗或与其他治疗药物联合使用的临床试验。在这篇综述中，我们提供了PARP抑制剂在前列腺癌以及尿路上皮癌中的理论依据、疗效和安全性数据。
相似文献
1
PARP Inhibitors in Prostate and Urothelial Cancers.
Front Oncol. 2020 Feb 7;10:114. doi: 10.3389/fonc.2020.00114. eCollection 2020.
2
When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Eur Urol Oncol. 2020 Oct;3(5):594-611. doi: 10.1016/j.euo.2020.07.005. Epub 2020 Aug 17.
3
PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
Genes (Basel). 2019 Jul 26;10(8):565. doi: 10.3390/genes10080565.
4
The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Int J Mol Sci. 2022 Jul 23;23(15):8125. doi: 10.3390/ijms23158125.
5
Advances in the use of PARP inhibitor therapy for breast cancer.
Drugs Context. 2018 Aug 8;7:212540. doi: 10.7573/dic.212540. eCollection 2018.
6
[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Bull Cancer. 2015 Oct;102(10):863-73. doi: 10.1016/j.bulcan.2015.07.012. Epub 2015 Sep 15.
7
Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
Curr Opin Obstet Gynecol. 2018 Feb;30(1):7-16. doi: 10.1097/GCO.0000000000000428.
8
Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
Expert Opin Ther Targets. 2019 Sep;23(9):773-785. doi: 10.1080/14728222.2019.1654458. Epub 2019 Aug 13.
9
Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology.
Pharmacogenomics. 2021 Dec;22(18):1237-1250. doi: 10.2217/pgs-2021-0119. Epub 2021 Nov 3.
10
Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer.
Curr Oncol Rep. 2022 Nov;24(11):1619-1631. doi: 10.1007/s11912-022-01305-0. Epub 2022 Aug 6.
引用本文的文献
1
Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma.
Molecules. 2024 Apr 22;29(8):1896. doi: 10.3390/molecules29081896.
2
Current and Future Landscape of Perioperative Treatment for Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2023 Jan 17;15(3):566. doi: 10.3390/cancers15030566.
3
Comparison of Homologous Recombination Repair Gene Next-Generation Sequencing Analysis in Patients With Metastatic Castration-Resistant Prostate Cancer Between Local and Central Laboratories in Korea.
Ann Lab Med. 2023 Jan 1;43(1):64-72. doi: 10.3343/alm.2023.43.1.64. Epub 2022 Sep 1.
4
Implications of targeted next-generation sequencing for bladder cancer: report of four cases.
J Genet Eng Biotechnol. 2021 Jun 21;19(1):91. doi: 10.1186/s43141-021-00182-7.
5
Characteristics of BRCA1/2 pathogenic germline mutations in chinese NSCLC patients and a comparison with HBOC.
Hered Cancer Clin Pract. 2021 Feb 9;19(1):16. doi: 10.1186/s13053-021-00174-1.
6
Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC.
Ther Adv Med Oncol. 2020 Nov 11;12:1758835920970845. doi: 10.1177/1758835920970845. eCollection 2020.
7
Targeting DNA Damage Response in Prostate and Breast Cancer.
Int J Mol Sci. 2020 Nov 4;21(21):8273. doi: 10.3390/ijms21218273.
8
RAD51-Mediated DNA Homologous Recombination Is Independent of Mutational Status.
Cancers (Basel). 2020 Oct 29;12(11):3178. doi: 10.3390/cancers12113178.
9
PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
Medicines (Basel). 2020 Aug 31;7(9):54. doi: 10.3390/medicines7090054.
10
Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma.
Cancers (Basel). 2020 Jun 2;12(6):1449. doi: 10.3390/cancers12061449.
本文引用的文献
1
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol. 2020 Jan;21(1):162-174. doi: 10.1016/S1470-2045(19)30684-9. Epub 2019 Dec 2.
2
PARP Inhibition in Cancer: An Update on Clinical Development.
Target Oncol. 2019 Dec;14(6):657-679. doi: 10.1007/s11523-019-00680-2.
3
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
N Engl J Med. 2019 Jul 25;381(4):338-348. doi: 10.1056/NEJMoa1817323.
4
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature. 2019 May;569(7757):503-508. doi: 10.1038/s41586-019-1186-3. Epub 2019 May 8.
5
BRCA2 and Other DDR Genes in Prostate Cancer.
Cancers (Basel). 2019 Mar 12;11(3):352. doi: 10.3390/cancers11030352.
6
Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
Eur Urol. 2019 Oct;76(4):452-458. doi: 10.1016/j.eururo.2019.02.002. Epub 2019 Feb 21.
7
New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment.
J Exp Clin Cancer Res. 2019 Feb 22;38(1):91. doi: 10.1186/s13046-019-1089-z.
8
Cancer statistics, 2019.
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
9
Synthetic lethal therapies for cancer: what's next after PARP inhibitors?
Nat Rev Clin Oncol. 2018 Sep;15(9):564-576. doi: 10.1038/s41571-018-0055-6.
10
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol. 2018 Jul;19(7):975-986. doi: 10.1016/S1470-2045(18)30365-6. Epub 2018 Jun 4.
Zotero 插件